Format

Send to

Choose Destination
See comment in PubMed Commons below
Lung Cancer. 2013 Nov;82(2):362-4. doi: 10.1016/j.lungcan.2013.08.007. Epub 2013 Aug 15.

Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.

Author information

1
Medical Oncology Department, CAL, University Hospital, Nice, France.

Abstract

A case of locally advanced non-small-cell lung carcinoma (NSCLC) was inadequately controlled with cisplatin, bevacizumab and pemetrexed chemotherapy. Following identification of a mutation of the echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) gene, crizotinib was then administered as targeted treatment. Kidney function was normal at diagnosis and during the first line therapy. The administration of crizotinib coincided on two occasions with a conspicuous rise in the serum creatinine level. Urinary protein over creatinine ratio was 0.31 g/g with 22% albumin and macroscopic hematuria. A kidney biopsy was performed at the time of the second episode of renal impairment which showed acute tubular necrosis (ATN) indicating recent renal injury together with a mononuclear cell infiltrate consistent with ongoing repair related to a previous insult. The renal lesions were closely related temporally to crizotinib administration, supporting a causative role for crizotinib in the acute renal injury and this phenomenon has not previously been described.

KEYWORDS:

Acute kidney injury; Acute tubular necrosis; Adverse drug reaction; Chemotherapy; Crizotinib; EML4-ALK protein; Non-small-cell lung carcinoma; Tyrosine kinase inhibitor

PMID:
24001942
DOI:
10.1016/j.lungcan.2013.08.007
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center